An observational study in Episodic Migraine and Chronic Migraine, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Migraine Disorders with a site in Austria — 4 open to participants now, 6 under way, 2 of them phase 3. Migraine Disorders · Austria.
Among the 20 studies in Migraine Disorders with a site in Austria, this one is the only one that started in 2020, is one of 3 observational ones, and was the 9th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 20 studies in Migraine Disorders with a site in Austria are open now. Recruiting first, the newest first:
Brightmind.AI · Sites in Austria
Ages 18–65
Austrian Migraine Registry Collaboration · Sites in Austria
Ages 18+
Bernhard Taxer · Sites in Austria
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 621 across the 17 interventional studies, 120 across the 3 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Migraine Disorders with a site in Austria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Migraine Disorders with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) class of drugs affects the autonomic functions. The aim is not to investigate the effect of CGRP-mAb on migraine frequency. Calcitonin gene-related peptide (CGRP) is a neurotransmitter in the nervous system that plays an essential role in the development of migraine headache. Monoclonal antibodies can block the function of this messenger substance. Several studies have shown that this blockade leads to a reduction in the frequency of migraine.
In addition to its role in migraine, CGRP also acts on the blood vessels and the autonomic nervous system. The autonomic nervous system is responsible for everything we have no control over in our body. This includes everything from heart rate and blood pressure to our digestion.
Background:
Headache disorders are among the leading illnesses contributing to the Global Burden of Disease. They are so common, that they rank second in prevalence and years lived with disability. Additionally, headache disorders are the second-ranked cause of years lived with disability in females, worldwide. Migraines are so prevalent in human history that there exist records from the ancient Egyptians documenting symptoms of attacks.
Migraines are classified by the International Headache Society in their International Classification of Headache Disorders 3 (ICHD-3) guidelines as: migraine without aura, migraine with aura, chronic migraine, and probable migraine. They are considered episodic if headache is present on fewer than 15 days per month; or chronic if headache occurs "on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of migraine headache". Until now, researchers have made numerous connections between migraines and the autonomic symptoms that manifest both ictally and interictally. Research, using standardized autonomic tests, has improved our ability to evaluate these symptoms. Furthermore, strides have been made to map migraine attacks and visualize them. Finally, research directed towards the molecular mechanism of these attacks has also yielded results.
Current recommendations for pharmacological migraine treatment comprise abortive drugs (i.e. non-opioid analgesics and triptans) and prophylactic medication (e.g. beta-blockers, calcium-channel blockers, antidepressants, anti-seizure medications and onabotulinumtoxin A). None of these prophylactic drugs were specifically developed against migraine. Their dosages must be slowly increased, since these medications can lead to fatigue, depression, nausea, insomnia, decreased libido, along with many other side effects specific to the individual modalities. Therefore, a more favorable treatment is required.
Molecular evidence is accumulating that calcitonin gene-related peptide (CGRP) contributes greatly to this pathophysiology. In tandem, evidence of CGRP's role in other physiological mechanisms has also been elucidated. These include roles in: vasodilation, cardioprotection, blood pressure regulation, sepsis, wound healing, bone re-growth, among others. The majority of CGRP is sequestered at the trigeminal level; however, it is released from both peripheral and central nerve terminals. As such, investigation of parasympathetic - and reciprocally, the sympathetic - autonomic nervous system (ANS) pathways are of particular interest. It is, however, CGRP's connection to migraines which has, consequently, led to the development of several CGRP receptor antagonists, an anti-CGRP-receptor monoclonal anti-body (mAb) and several anti-CGRP-ligand mAbs.
Only recently have anti-CGRP antibodies been approved by the European Medicines Agency. There are three prophylactic pharmaceutical options targeting CGRP currently available and reimbursed in Austria. Erenumab (Aimovig® - anti-receptor) is available since September 2018, Galcanezumab (Emgality® - anti-ligand) since March 2019 and Fremanezumab (Ajovy® - anti-ligand) since May 2019. Randomized controlled trials are also ongoing for Eptinezumab (anti-ligand). The largest benefit provided by anti-CGRP monoclonal antibodies is that they are relatively well-tolerated - shown to reduce the frequency of attacks experienced by the patient each month. As such, CGRP-related monoclonal antibodies are being increasingly utilized; however, there is a very limited amount of exogenous medication that does not have unwanted interactions once administered into the body.
In randomized, placebo-controlled studies on the efficacy and tolerability of anti-CGRP monoclonal antibodies (ant-CGRP-mAbs), no serious side effects were found. Those that were found and are provided in official documentation, include: injection site reactions, constipation, muscle cramps, vertigo, pruritus, and urticaria. Meanwhile other recipients of the therapy reported: nasopharyngitis, infection, sinusitis, fatigue, hypertension, nausea, arthralgia, back pain, and migraine. Due to potent vasodilative functions of CGRP, a list of contraindications was created. This list includes: manifestation of vascular diseases (myocardial infarction, unstable angina pectoris, stroke, transient ischemic attacks, coronary bypass surgery or other revascularization procedures within the last 12 months) and poorly controlled hypertension. It is still unknown what the potential course and prognosis of de novo myocardial infarction, cerebral ischemia and subarachnoid hemorrhage could be for patients receiving anti-CGRP medication. Calcitonin gene related peptide has been shown to promote angio- and lymphangiogenesis. Post-ischemic angiogenesis has been observed with the release of CGRP. Meanwhile, CGRP has been shown to improve lymphangiogenesis in secondary lymphedema. Further warnings concerning pregnancy and the desire to have children, potential damage to the blood-brain barrier (e.g. meningitis, stroke, after neurosurgery) and recent peripheral nerve lesions have arisen; and, appropriate longitudinal observations are only now being reported.
While autonomic symptoms of migraine are well known - such as: nausea/vomiting, hyperhidrosis, pallor, palpitations, and lightheadedness - the methods with which earlier investigations evaluated them are not as well-standardized. A review by Miglis, from 2018, summarizes that most studies of autonomic function in migraine showed reduced sympathetic function in migraineurs; while others, reported increased sympathetic function; and others still, showed normal sympathetic function. Likewise, the majority of studies reported normal parasympathetic cardiovagal function; while others, reported decreased parasympathetic function. Miglis goes on to describe in his review, a variety of investigations used to arrive at these conclusions - heart rate variability (HRV) studies, autonomic cardiovascular reflex testing and imagining studies. These paradoxical results can be interpreted as being caused by methodological inconsistency between investigations. For example, some HRV investigations elect to use 24h continuous electrocardiogram (ECG) monitoring, while others use ECG measurements during the head-up tilt test to gather HRV data. This results in the uncoordinated use of different methods, which ultimately illustrates the need for consistent, standardized testing of the ANS in migraine studies.
Considering the concerns expressed by Tringali and Navarra - to observe the long-term effects of CGRP-inhibition, as it pertains to autonomic function - there currently exists great potential to address this gap in knowledge. Therefore, this non-therapeutic biomedical study aims to address this lack of literature, by obtaining and comparing standardized healthy CAD values with those of migraineurs, observing CAD values in migraine patients off prophylactic therapy - in both the ictal and peri-ictal phases of the migraine cycle - and then comparing baseline CAD values with CAD values during anti-CGRP therapy.
Primary explorative questions:
This study will aim to address the autonomic aspects of migraine, through a newly published objective autonomic function scoring. It aims to explore whether differences exist in the autonomic function values (CAD) between healthy people and migraine patients. Furthermore, it will aim to explore the CAD differences between migraine attack-phases (peri-ictal and interictal). Lastly, over the course of 5 months, this study will explore whether inhibition of CGRP - as an anti-CGRP-mAb class-effect - affects these autonomic function scores. The following questions will be answered:
Q1: Is there a difference in CAD values between healthy controls and migraine patients off prophylactic medication?
Q2: Is there a difference in the CAD values of migraine patients during a migraine attack (peri-ictal phase) and their respective CAD values between attacks (interictal phase)?
Q3: Is there a difference in CAD values of migraine patients before anti-CGRP treatment and during treatment with anti-CGRP-mAbs (class effect on autonomic functions)?
Secondary Question:
To support the examination of these three questions, validated questionnaires will be used to assess the subjective effect of anti-CGRP-mAbs on: monthly migraine and headache days, autonomic function, quality of life and psychiatric symptoms.
Study Proceudres:
For the patients the study will comprise of: 1) a patient screening phase (following recruitment); 2) two clinical baseline visits (day 0 and one day between days 1 and 30); 3) an evaluation visit (month 5), which will also serve as the End of Study (EOS); and 4) a telephone follow-up. For the healthy controls the study will comprise: 1) a patient screening phase; 2) one testing visit (day 0); and 3) a telephone follow-up.
Patients diagnosed to be suffering from migraine without aura, migraine with aura or chronic migraine according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3). Patients will be ages 18 to 64. It is mandatory they have valid health insurance provided by one of the insurance institutions of Austria.
Controls must be healthy (free of any diagnosed chronic disease or acute infection requiring medication), chosen to be as similar as possible to migraine patients, in terms of age and sex
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients who have been diagnosed with migraine without aura or migraine with aura according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
Drug: Erenumab · Drug: Galcanezumab · Drug: Fremanezumab
All patients who have been diagnosed with chronic migraine (≥15 headache days per month 8 of which with migrainous features) according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
Drug: Erenumab · Drug: Galcanezumab · Drug: Fremanezumab
Controls must be healthy (free of any diagnosed chronic disease, acute infection requiring medication, family history or personal history of migraine), chosen to be as similar as possible to migraine patients, in terms of age and sex.
anti-CGRP-receptor monoclonal anti-body
Also known as: Aimovig®
anti-CGRP-ligand monoclonal anti-body
Also known as: Emgality®
anti-CGRP-ligand monoclonal anti-body
Also known as: Ajovy®
Change from Day 0 Cardiovagal Autonomic Dysfunction (CAD) at 5 months
It is derived from the Composite Autonomic severity scale (CASS), an "unbiased and full quantification" of the autonomic functions in the cardiovagal, adrenergic and sudomotor domain. The total CASS score has "a direct clinical meaning since it ranks the generalized dysautonomia as mild, moderate and severe". By isolating two of the indices of the CASS - adrenergic index (AI) and cardiovagal index (CI) - one can quantify the Cardiovascular Autonomic Dysfunction (CAD). Results are referred to as normal (CAD total score = 0) or abnormal. Abnormal values are considered 1-7, indicating presence of CAD.
Time frame: Day 0, Month 5 (EOS)
Change from Days 1-31 Cardiovagal Autonomic Dysfunction (CAD) at 5 months
It is derived from the Composite Autonomic severity scale (CASS), an "unbiased and full quantification" of the autonomic functions in the cardiovagal, adrenergic and sudomotor domain. The total CASS score has "a direct clinical meaning since it ranks the generalized dysautonomia as mild, moderate and severe". By isolating two of the indices of the CASS - adrenergic index (AI) and cardiovagal index (CI) - one can quantify the Cardiovascular Autonomic Dysfunction (CAD). Results are referred to as normal (CAD total score = 0) or abnormal. Abnormal values are considered 1-7, indicating presence of CAD.
Time frame: Days 1-31, Month 5 (EOS)
Change from Days 0 Cardiovagal Autonomic Dysfunction (CAD) at Days 1-31
It is derived from the Composite Autonomic severity scale (CASS), an "unbiased and full quantification" of the autonomic functions in the cardiovagal, adrenergic and sudomotor domain. The total CASS score has "a direct clinical meaning since it ranks the generalized dysautonomia as mild, moderate and severe". By isolating two of the indices of the CASS - adrenergic index (AI) and cardiovagal index (CI) - one can quantify the Cardiovascular Autonomic Dysfunction (CAD). Results are referred to as normal (CAD total score = 0) or abnormal. Abnormal values are considered 1-7, indicating presence of CAD.
Time frame: Day 0, Days 1-31
Change from Days 0 Composite Autonomic Symptom Scale 31 (COMPASS-31) at 5 months
The Composite Autonomic Symptom Scale 31 is a simplified autonomic symptom scoring scheme that follows a homogeneous pattern of scoring throughout the instrument. It quantifies 6 domains: Orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions. The 6 domains sum to a total COMPASS-31 score of 0 to 100. A higher score indicates greater autonomic impairment (worse score).
Time frame: Day 0, Month 5 (EOS)
Change from Days 0 Day Impact Questionnaire (HIQ) at 5 months
The Headache Impact Questionnaire is a six-item questionnaire which provides group-level comparisons, patient-level screening, and is responsive to changes in impact of days with headache. The HIQ items cover a substantial range of headache impact as defined by a much larger pool of items and include content areas found in most widely used tools for measuring headache impact. The 6 items sum to a total HIQ score of 0 to 24. A higher score indicates a greater burden of headache (worse score).
Time frame: Day 0, Month 5 (EOS)
Change from Days 0 Non-Headache Day Impact Questionnaire (Non-HIQ) at 5 months
The Non-Headache Day Impact Questionnaire is a six-item questionnaire which provides group-level comparisons, patient-level screening, and is responsive to changes in days without headache. The 6 items sum to a total non-HIQ score of 0 to 24. A higher score indicates a greater burden on headache-free days (worse score).
Time frame: Day 0, Month 5 (EOS)
Change from Days 0 Migraine Disability Assessment Scale (MIDAS) at 5 months
The Migraine Disability Assessment Scale is a 5-item self-administered questionnaire. It is used to quantify headache-related disability; and, has been shown as highly reliable in population-based samples of migraine headache sufferers. The score is the sum total of days affected by migraine. The 5 items sum to a total MIDAS score of 0 to 155. A higher score indicates greater headache-related disability (worse score).
Time frame: Day 0, Month 5 (EOS)
Change from Days 0 Depression Anxiety Stress Scale (DASS) at 5 months
The Depression Anxiety Stress Scale is a set of three self-report scales designed to measure the negative emotional states of depression, anxiety and stress. The DASS was constructed to further the process of defining, understanding, and measuring the pervasive and clinically significant emotional states usually described as depression, anxiety and stress. The 21-item sum is multiplied by a factor of 2, to result in a total DASS score of 0 to 126. Scoring is used to discriminate between the three related states of depression, anxiety and stress; with a higher score indicating greater indication of the three emotional states (worse score).
Time frame: Day 0, Month 5 (EOS)
Plan to share: No
Started Oct 2020 (actual). Primary completion is estimated for Dec 2025, 62 months after the start.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 62 months is above that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →